Vertex Pharmaceuticals (VRTX) is facing pushback from cystic fibrosis patients and their families as it plays hardball with the U.K. government over the cost of its medicines.
In a highly publicized move designed to tug heartstrings, an 8-year-old boy and his mother gave an orchestrated round of media interviews to implore the company to lower the price of its Orkambi treatment, which the government calls too expensive.
About the Author Reprints
